HexemBio
Latest round
- Seed
Last raised
- Apr 2026
Total raised
- $10M
Investors
- 3
About HexemBio
Based in New York, US and co-founded in 2024 by Gabriel Levesque Tremblay (CEO), Samira Kiani (CTO), Mo Ebrahimkhani (CSO), Samet Yildirim (CBO), and Joshua Hislop, HexemBio Inc. is a biotechnology company developing regenerative therapies designed to rejuvenate aging blood-forming stem cells using its Synthetic Human Yolk Sac platform. In September 2026, HexemBio Inc. Hexem Bio specializes in innovative stem cell therapy, particularly focusing on rejuvenating aged Hematopoietic Stem Cells (HSCs) to restore their youthful functionality. Their core offering is the Rejuvenated Stem Cell Therapy, which aims to enhance the production of healthy blood cells, including stronger white blood cells for improved immunity, red blood cells for better organ health, and increased platelet production for faster recovery. The therapy employs the Yolk Sac Method to access the early developmental state of HSCs, validated through extensive animal studies. Target markets include healthcare facilities and research institutions that cater to patients in need of advanced regenerative therapies, primarily in North America and parts of Europe. Hexem Bio's revenue model revolves around partnerships with healthcare providers and research institutions that implement their stem cell therapies. Transactions are structured as direct sales or partnerships, granting clients access to the Rejuvenated Stem Cell Therapy as a specialized service. The company collaborates directly with medical facilities to establish agreements that outline service delivery and pricing, which reflect the advanced nature of the therapy and tailored client solutions.
Who invested in HexemBio
3 investors across 2 rounds
See all investors in HexemBio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about HexemBio
Who invested in HexemBio?
HexemBio has 3 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has HexemBio raised?
HexemBio has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did HexemBio last raise money?
HexemBio's most recent round on record is a Seed, in Apr 2026.
What does HexemBio do?
Based in New York, US and co-founded in 2024 by Gabriel Levesque Tremblay (CEO), Samira Kiani (CTO), Mo Ebrahimkhani (CSO), Samet Yildirim (CBO), and Joshua Hislop, HexemBio Inc.
Where is HexemBio headquartered?
HexemBio is headquartered in New York, US.
Which VCs invest in companies like HexemBio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at HexemBio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like HexemBio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.